- Home
- DOMO vs TNGX Comparison
DOMO vs TNGX Comparison
Compare DOMO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOMO | TNGX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.0M | 1.4B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | DOMO | TNGX |
|---|---|---|
| Price | $9.01 | $9.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $14.38 | $12.50 |
| AVG Volume (30 Days) | 896.1K | ★ 2.6M |
| Earning Date | 12-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,002,000.00 | $66,501,000.00 |
| Revenue This Year | $2.32 | $53.01 |
| Revenue Next Year | $2.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 53.29 |
| 52 Week Low | $6.01 | $1.03 |
| 52 Week High | $18.49 | $11.20 |
Technical Indicators
Market Signals| Indicator | DOMO | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 29.57 | 52.39 |
| Support Level | $8.40 | $8.89 |
| Resistance Level | $11.88 | $10.22 |
| Average True Range (ATR) | 0.55 | 0.63 |
| MACD | -0.15 | -0.14 |
| Stochastic Oscillator | 17.53 | 20.91 |
Price Performance
Historical ComparisonAbout DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.